financetom
Business
financetom
/
Business
/
Advanced Micro Devices' Analyst Day Should Give Clarity on MI450 Opportunity, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Advanced Micro Devices' Analyst Day Should Give Clarity on MI450 Opportunity, Morgan Stanley Says
Nov 5, 2025 8:29 AM

11:08 AM EST, 11/05/2025 (MT Newswires) -- Advanced Micro Devices ( AMD ) had a good quarter as expected, but all eyes are on its analyst day next week, which should give clarity on the value proposition of the MI450 rack scale and the benefits of the ZT Systems acquisition, Morgan Stanley said in a Wednesday note.

The company's overall financial results aligned with expectations except for gaming, which performed slightly better than anticipated, Morgan Stanley analysts said.

The server market remains strong, and AMD is driving strong value growth in PCs, the analysts said. They added that the embedded segment, which includes specialized computing applications, is expected to see a cyclical recovery with the company confirming growth next year.

On the artificial intelligence front, AMD returned to year-over-year growth in Q3 after declines in H1. The company is still "lackluster" compared to its peers, with Nvidia ( NVDA ) and Broadcom's ( AVGO ) Application-Specific Integrated Circuits growing much faster, according to the note.

The analysts said they project continued share gains in notebook and server processors in 2025 and 2026 as AMD continues to execute on its product roadmap. The company's core business should accelerate significantly, driven by the return of server upgrades and ongoing growth in the PC market, while conditions in gaming and embedded markets are anticipated to normalize.

AMD's AI business, particularly with new MI400 products, should gain momentum in 2026, but maintaining leadership in performance is critical for its success in the segment, the note said.

Morgan Stanley maintained the company's stock rating at equal-weight and raised the price target to $260 from $246.

Price: 247.33, Change: -2.72, Percent Change: -1.09

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Novo Nordisk has mitigation plans to minimize disruption from port strikes
Novo Nordisk has mitigation plans to minimize disruption from port strikes
Oct 2, 2024
(Reuters) -Danish drugmaker Novo Nordisk said on Tuesday it has mitigation plans in place to minimize or prevent any disruption to its production due to sea port strikes in the United States. The maker of popular drugs, Wegovy and Ozempic, plans to ship its products to and from the U.S. via air freight, a company spokesperson said. The company imports...
--Corning Keeps Quarterly Dividend at $0.28 Per Share; Payable Dec. 13 to Shareholders of Record on Nov. 15
--Corning Keeps Quarterly Dividend at $0.28 Per Share; Payable Dec. 13 to Shareholders of Record on Nov. 15
Oct 2, 2024
09:59 AM EDT, 10/02/2024 (MT Newswires) -- Price: 44.80, Change: +0.26, Percent Change: +0.57 ...
RTX's Raytheon Unit Wins Semiconductor Development Contract From DARPA
RTX's Raytheon Unit Wins Semiconductor Development Contract From DARPA
Oct 2, 2024
09:56 AM EDT, 10/02/2024 (MT Newswires) -- RTX's (RTX) Raytheon unit said Wednesday that it won a three-year, two-phase contract from the US Department of Defense's Defense Advanced Research Projects Agency, or DARPA, to develop foundational ultra-wide bandgap semiconductors. No financial terms were disclosed. The company said contract work will be carried out at its foundry in Andover, Massachusetts, with...
Johnson & Johnson Says Study Shows Erleada Provides 'Significant' Prostate Cancer Survival Over Enzalutamide
Johnson & Johnson Says Study Shows Erleada Provides 'Significant' Prostate Cancer Survival Over Enzalutamide
Oct 2, 2024
09:57 AM EDT, 10/02/2024 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Wednesday results from a study showed its Erleada, or apalutamide, provided a 'statistically significant overall survival benefit' at 24 months compared with enzalutamide in patients with metastatic castration-sensitive prostate cancer. Johnson & Johnson ( JNJ ) said the head-to-head study of apalutamide and enzalutamide included nearly...
Copyright 2023-2026 - www.financetom.com All Rights Reserved